Acute leukemia is a heterogeneous group of disease reflecting stem cell of origin, capacity of maturation and commitment to a specific lineage. Leukemic cells may show early or minimal differentiation and some diagnostic entities can easily be confused with others because of their atypical immunophenotype. In particular, it is well established that some stem cell, myeloid or lymphoid antigens can be expressed on poorly differentiated acute leukemia like immature blastic plasmacytoid dendritic cell neoplasm (BPDCN) and early T-cell precursor leukemia (ETP-ALL). These entities associated with a poor prognosis can be misdiagnosed as acute myeloid leukemia with minimal differentiation (AML-M0) if proper immunophenotyping panels are not routinely performed.

Many laboratories still use their own, non-standardized, laboratory developed antibody panels. In this webinar Rafik Terra will explain how the use of the EuroFlow™ standardized approach has the potential to improve the diagnostic accuracy of rare entities like BPDCN and ETP-ALL.

Rafik Terra, Ph.D in Immunology/Biomedical Sciences, has extensive experience in Clinical Flow Cytometry. Besides his current position of Scientific Director of the Flow Cytometry Laboratory at Maisonneuve Rosemont Hospital, he works as a Teacher and Guest Lecturer for a number of hospitals and for the University of Montreal (UdeM) as well as a Consultant for different companies.

11 AM GMT-4 (Montréal, Canada)
4 PM GMT+1 (Madrid, Spain)
3 PM GMT (London, United Kingdom)